Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. (CMMB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cmmb · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.81
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.78 | ↓ 1.46% |
1-day model range: $1.77–$1.8. Peak: $1.8 (-1.46%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $1 | -67.2% |
| 2030 | $1 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CMMB · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-27 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-05-16 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-02-20 | Maxim Group | Maintains | Buy→Buy |
| 2024-11-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2024-05-06 | Oppenheimer | Upgrade ↑ | Perform→Outperform |
| 2024-03-08 | Oppenheimer | Maintains | Perform→Perform |
| 2023-06-07 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2023-04-18 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-03-10 | Oppenheimer | Maintains | Outperform→Outperform |
| 2021-12-07 | Aegis Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Chemomab Therapeutics Ltd. (CMMB) stock. Of the recent 12 rating actions, 1 were upgrades and 1 were downgrades. 4 analysts currently cover CMMB.
Analyst Recommendation Trends
CMMB analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$24M
Revenue Next Year
$36M
↑ 48.4% YoY
EPS This Year
$-0.02
EPS Next Year
$-0.03
↑ 50.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CMMB EPS of $-0.02 for the current fiscal year, based on estimates from 1 analysts. The CMMB revenue forecast is $24M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CMMB stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CMMB price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CMMB short-term stock prediction for tomorrow is $1.78 (-1.46%). The CMMB stock price prediction for 2027 estimates an average of $1. The CMMB stock prediction for 2030 projects a range of $1–$1.
Chemomab Therapeutics Ltd. trades on NASDAQ under the ticker CMMB. The CMMB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CMMB forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month CMMB price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.81.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.